Skip to main content
SpringerLink
Log in

Glycoprotein IIb/IIIa Receptor Inhibition in Interventional Cardiology

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Verstraete M, Zoldhelyi P. Novel antithrombotic drugs in development. Drugs 1995;49:856–884.

    Google Scholar 

  2. Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb IIIa complex. Blood 1988;71:831–843.

    Google Scholar 

  3. Weiss HJ, Hawiger J, Ruggeri ZM, et al. Fibrinogen-independent platelet adhesion and thrombus formation on subendothelium mediated by glycoprotein IIbIIIa complex at high shear rate. J Clin Invest 1989;83:288–297.

    Google Scholar 

  4. McCrary JK, Nolasco LH, Hellums JD, et al. Direct demonstration of radio labeled von Willebrand factor binding to platelet glycoprotein Ib and IIbIIIa in the presence of shear stress. Ann Biomed Eng 1995;23:787–793.

    Google Scholar 

  5. Giles H, Smith RE, Martin JF. Platelet glycoprotein IIbIIIa and size are increased in acute myocardial infarction. Eur J Clin Invest 1994;24:69–72.

    Google Scholar 

  6. Tschoepe D, Schultheiss HP, Kolarov P, et al. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation 1993;88: 37–42.

    Google Scholar 

  7. Harrington RA, Ohman EM, Sigmon KN, et al. Intensity of inhibition of the platelet glycoprotein IIbIIIa receptor differ among disease states. Circulation 1995;92:I488.

    Google Scholar 

  8. Lefkovitz J, Plowai EF, Topol EJ. Platelet glycoprotein IIbIIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553–1559.

    Google Scholar 

  9. Peter K, Schwartz M, Majer P, Kohler B, Nordt T, Bode C. The antibody fragment c7E3 (ReoPro) binds to activated and nonactivated Mac-1 on granulo-and monocytes and blocks Mac-1-mediated cell adhesion and aggregation. J Am Coll Cardiol 1997;29:241A.

    Google Scholar 

  10. The EPIC investigators. Use of monoclonal antibody directed against the platelet glycoprotein IIbIIIa receptor in high risk coronary angioplasty. N Engl J Med 1994;330: 956–961.

    Google Scholar 

  11. Topol EJ, Califf RM, Weisman HF, et al. for the EPIC investigators. Randomized trial of coronary intervention with antibody against platelet IIbIIIa integrin for reduction of clinical restenosis: Results at six months. Lancet 1994; 343:881–886.

    Google Scholar 

  12. Topol EJ, Ferguson JJ, Weisman HF et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin b3 blockade with percutaneous coronary intervention. JAMA 1997;278:479–484.

    Google Scholar 

  13. Strömblad S, Becker JC, Yebra M, Brooks PC, Cheresh DA. Suppression of p53 activity and p21 expression by vascular cell integrin αvβ3 during angiogenesis. J Clin Invest 1996; 98:426–433.

    Google Scholar 

  14. Speir E, Modali R, Huang ES, Leon MB, Shawl F, Finkel T, Epstein SE. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 1994;265: 391–394.

    Google Scholar 

  15. Zhou YF, Leon MB, Waclawiw MA, Popma JJ, Yu ZX, Finkel T, Epstein SE. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med 1996;335:624–630.

    Google Scholar 

  16. Lefkovitz J, Stoner GL, Anderson KM, et al. Can conjunctive platelet glycoprotein IIb/IIIa receptor blockade improve outcomes of coronary interventions for restenotic lesions? Circulation 1995;92:I607.

    Google Scholar 

  17. Challapalli RM, Eisenberg MJ, Sigmon K, et al. Platelet glycoprotein IIb/IIIa monoclonal antibody (c7E3) reduces distal embolization during percutaneous interventions of saphenous veins grafts. Circulation 1995;92:I607.

    Google Scholar 

  18. Lefkovits J, Blankenship JC, Anderson KM et al. Increased risk of non-Q-wave myocardial infarction after directional atherectomy is platelet dependent: Evidence from the EPIC trial. J Am Coll Cardiol 1996;28:849–855. 19. Ferguson J. Meeting highlights. Circulation 1995;91: 2857–2861.

    Google Scholar 

  19. Ferguson J. Meeting highlights. Circulation 1995;91: 2857–2857.

    Google Scholar 

  20. Bednar B, Bednar RA, Cook JJ, et al. Drug-dependent antibodies against GPIIb/IIIa induce thrombocytopenia. Circulation 1996;94:I99.

    Google Scholar 

  21. Berkowitz SD, Sane DC, Shavender JH, et al. Analysis of the occurrence and clinical significance of thrombocytopenia with cc7E3 (abciximab) in the EPIC trial. J AmColl Cardiol 1996;27:82A.

    Google Scholar 

  22. Lincoff AM, Tcheng JE, Califf RM, et al. for the PROLOG Investigators. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. Am J Cardiol 1997;79:286–291.

    Google Scholar 

  23. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336: 1689–1696.

    Google Scholar 

  24. Lincoff AM. Results of the interim analysis of the EPILOG trial. J Am Coll Cardiol 1996;27(Suppl. A):xxi.

    Google Scholar 

  25. Ferguson J. Meeting highlights. Circulation 1996;94:1–4.

    Google Scholar 

  26. Ferguson J. Cardiovascular news. Circulation 1996;93: 637.

    Google Scholar 

  27. The CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997;349:1429–1435.

    Google Scholar 

  28. Brener SJ, Barr LA, Burchenal JEB, et al. for the RAPPORT Investigators. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 1998;98:734–741.

    Google Scholar 

  29. Lincoff MA, Tceng JE, Califf RM, et al. The EPISTENT trial at 6 months: Relative and combined effects of abciximab and stenting on reduction of acute ischemic events and late revascularization. Circulation 1998;98:I767.

    Google Scholar 

  30. Blankenship JC, Godfrey NK, Balog C, et al. How did abciximab decrease ischemic complications during coronary intervention in EPISTENT? Analysis of in lab adverse events. Circulation 1998;98:I573.

    Google Scholar 

  31. Lincoff MA, Moliterno DJ, Ellis SG, et al. 6 month angiographic outcome with abciximab and stents: The EPISTENT angiographic substudy. Circulation 1998;98:I768.

    Google Scholar 

  32. Lincoff MA, Booth JE, Godfrey NK, et al. Periprocedural myocardial infarctions prevented by IIb IIIa blockade are clinically and angiographically manifest and large: The EPISTENT experience. Circulation 1998;98:I766.

    Google Scholar 

  33. Ellis SG, Serruys PW, Popma JJ, et al. Can abciximab prevent neointimal proliferation in Palmaz-Schatz stents? The final ERASER results. Circulation 1997;96:I87.

    Google Scholar 

  34. Antman EM, Giugliano RP, McCabe CH, et al. Abciximab (ReoPro) potentiates thrombolysis in ST elevation myocardial infarction: Results of the TIMI 14 trial. J Am Coll Cardiol 1998;31:191A.

    Google Scholar 

  35. Gibson M, Giugliano RP, Anderson K, Scherer JC, McCabe CH, Antman EM. Abciximab enhances thrombolysis: A comparison of abciximab alone versus abciximab plus low dose thrombolytics using the corrected TIMI frame count. Circulation 1998;98:I559.

    Google Scholar 

  36. Muhlestein JB, Gomez MA, Karagounis LA, Anderson JL. Abciximab for acute dissolution of thrombus. Circulation 1995;92:I607.

    Google Scholar 

  37. Barrett JS, Murphy G, Peerlinck K, et al. Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. Clin Pharmacol Ther 1994;56:377–388.

    Google Scholar 

  38. Kereiakes DJ, Kleiman NS, Ambrose J, et al. Randomized, double-blind, placebo-controlled dose-ranging study of Tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol 1996;27:536–542.

    Google Scholar 

  39. The RESTORE Investigators. The effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445–1453.

    Google Scholar 

  40. Gibson CM, Goel M, Cohen DJ, et al. Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. J AmColl Cardiol 1998; 32:28–34.

    Google Scholar 

  41. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM PLUS) study investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488–1497.

    Google Scholar 

  42. The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) study investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998;338:1498–1505.

    Google Scholar 

  43. Scarborough RM, Rose JW, Naughton MA, et al. Characterization of the integrin specificities of disintegrins isolated from American Pit Viper venoms. J Biol Chem 1993;268: 1058–1065.

    Google Scholar 

  44. Tcheng JE, Harrington RA, Kottke-Marchant K, et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIbIIIa blocker integrelin in elective coronary intervention. IMPACT investigators. Circulation 1995;91:2151–2157.

    Google Scholar 

  45. The IMPACT-II Investigators. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997; 349:1422–1428.

    Google Scholar 

  46. Ferguson JJ, McDonough TJ, Worley SJ, et al. Clinical outcome of “high-risk” versus elective patients undergoing percutaneous coronary intervention: Results from IMPACT II. J Am Coll Cardiol 1996;27:180A.

    Google Scholar 

  47. Teirstein PS, Yakubov SJ, Thel MC, et al. Platelet IIb/IIIa blockade with integrilin: Atherectomy patients. J Am Coll Cardiol 1996;27:334A.

    Google Scholar 

  48. Zidar JP, Kruse KR, Thel MC, et al. for the IMPACT II investigators. Integrelin for emergency coronary artery stenting. J Am Coll Cardiol 1996;27:138A.

    Google Scholar 

  49. Blankenship J, Mandak J, Aguirre F, et al. Vascular access site complications during angioplasty with glycoprotein IIb/IIIa receptor inhibition in the IMPACT II trial. J Am Coll Cardiol 1996;27:360A.

    Google Scholar 

  50. The PURSUIT trial investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436–443.

    Google Scholar 

  51. Austel V, Himmelsbach F, Müller TH. Nonpeptidic fibrinogen receptor antagonists. Drugs Future 1994;19:757–764.

    Google Scholar 

  52. Cox D, Aoki T, Seki J, Motoyama Y, Yoshida K. The pharmacology of integrins. Med Res Rev 1994;14:195–228.

    Google Scholar 

  53. Cannon CP. McCabe CH, Borzak S, et al. for the TIMI 12 investigators. A randomized trial of an oral platelet glycoprotein IIB/IIIa antagonist, sibrafiban, in patients post an acute coronary syndrome: Results of the TIMI 12 trial. Circulation 1998;97:340–349.

    Google Scholar 

  54. Simpfendorfer C, Kottke-Marchant K, Topol EJ. First experience with chronic platelet GPIIb/IIIa receptor blockade: A pilot study of xemilofiban, an orally active antagonist in unstable angina patients eligible for PTCA. J Am Coll Cardiol 1996;27:242A.

    Google Scholar 

  55. Kottke-Marchant K, Simpfendorfer C, Lowrie M, Burns D, Anders RJ. Sustaind but variable inhibition of platelet aggregation with xemilofiban, an oral GPIIb/IIIa receptor antagonist, in patients with unstable angina. Circulation 1995;92:I488.

    Google Scholar 

  56. Keriakes DJ, Kleiman N, Ferguson JJ, et al. Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment. Circulation 1997;96:1117–1121.

    Google Scholar 

  57. Keriakes DJ, Runyon JP, Kleiman NS, et al. Differential dose-response to oral xemilofiban after antecedent intravenous abciximab. Circulation 1996;94:906–910.

    Google Scholar 

  58. Müller TH, Weisenberger H, Brickl R, et al. Profound and sustained inhibition of platelet aggregation by fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, lefradafiban, in men. Circulation 1997;96:1130–1138.

    Google Scholar 

  59. Lefkovits J, Horrigan MC. Is the risk of intracerebral hemorrhage greater with direct thrombin inhibitor than with GPIIb/IIIa antagonist? A meta-analysis of recent clinical trials. Circulation 1995;92:I80.

    Google Scholar 

  60. Deckers J, Califf RM, Topol EJ, et al. Use of abciximab is not associated with an increase in the risk of stroke: Overview of three randomized trials. J Am Coll Cardiol 1997;29:241A.

    Google Scholar 

  61. Ferguson JJ. American Heart Association meetings 1998, Dallas, USA.

  62. Aggarwal RK, Ireland DC, Azrin MA, et al. Antithrombotic properties of stents eluting platelet glycoprotein IIb/IIIa antibody. Circulation 1995;92:I488.

    Google Scholar 

  63. Smith JW, Tachias K, Madison EL. Loop grafting to construct a variant of tissue-type plasminogen protein activator that binds platelet integrin alpha IIB beta 3. J Biol Chem 1995;270:30486–30490.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiovascular Division of the Department of Medicine, Allegheny General Hospital, Pittsburgh, Pennsylvania, USA

    C. Michael Gibson, John L. Moynihan, Eyas N. Al-Mousa, Michael Campsey, Rina Gandhi, Sabina Murphy, Scott Mattson, Kathryn A. Ryan, Rebecca Mesley, Jil Swanson, Mohammad Naveed Arshad & Susan J. Marble

Authors
  1. C. Michael Gibson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John L. Moynihan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eyas N. Al-Mousa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael Campsey
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rina Gandhi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sabina Murphy
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Scott Mattson
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kathryn A. Ryan
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Rebecca Mesley
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jil Swanson
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Mohammad Naveed Arshad
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Susan J. Marble
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gibson, C.M., Moynihan, J.L., Al-Mousa, E.N. et al. Glycoprotein IIb/IIIa Receptor Inhibition in Interventional Cardiology. J Thromb Thrombolysis 7, 287–302 (1999). https://doi.org/10.1023/A:1008935227780

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1008935227780

Keywords

Search

Navigation